JNJ Johnson & Johnson
Company Analysis
Latest News
Johnson & Johnson Reports TREMFYA Success, First Crohn’s Breakthrough in Decades
Johnson & Johnson reported positive Phase 3 FUZION study results for TREMFYA (guselkumab) at Digestive Disease Week 2026. The trial evaluated the drug in...
Johnson & Johnson Submits OTTAVA Robot to FDA Following Positive Human Trial
Johnson & Johnson reported positive results from the first clinical study of its OTTAVA™ soft-tissue surgical robotic system. The company presented these...
J&J Showcases Phase 3 Erleada Data at ASCO, Eyeing New Care Standards
Johnson & Johnson will present data from more than 20 clinical and real-world studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting....
Johnson & Johnson Halves Drug Lead Time with AI, Targeting Patent Expirations
Johnson & Johnson CIO Jim Swanson announced at the Reuters Momentum AI event that AI has halved the time required to generate new drug development leads. The...
Johnson & Johnson’s IMAAVY Wins FDA Priority Review, First for Rare Anemia
The U.S. Food and Drug Administration granted Priority Review for Johnson & Johnson’s supplemental Biologics License Application for IMAAVY (nipocalimab-aahu)....
Johnson & Johnson Expands MedTech Portfolio with Acquisition and AI Partnership
Johnson & Johnson acquired Atraverse Medical. The deal expands J&J’s MedTech cardiovascular portfolio into high-growth medical device markets. Atraverse...
Johnson & Johnson acquires Atraverse Medical, expanding heart rhythm treatment options
Johnson & Johnson entered a definitive agreement to acquire Atraverse Medical, a private firm specializing in left-heart access technology. The deal includes...
Johnson & Johnson eyes $10 billion boost, pending 2026 FDA approvals
Johnson & Johnson anticipates two critical FDA decisions in 2026. These approvals could increase the company's market capitalization by an estimated $10...
Johnson & Johnson Unveils AI-Powered Cardiac Imaging and Ablation Technology at Medical Conference
Johnson & Johnson will showcase its electrophysiology portfolio at the 2026 Heart Rhythm Society (HRS) Annual Meeting. The company will launch the CARTOSOUND...
J&J Defeats Bayer Lawsuit, Protecting Erleada Prostate Cancer Marketing
A U.S. judge rejected Bayer’s request to block Johnson & Johnson’s advertising for the prostate cancer drug Erleada. Bayer’s lawsuit alleged J&J falsely...
J&J Target Raised to $283, Morgan Stanley Cites Durable Earnings Growth
Morgan Stanley raised its price target for Johnson & Johnson to $283 from $267. The bank reiterated its Overweight rating on the shares. Analysts now value the...
Johnson & Johnson's first quarter 2026 revenue of $24.1B beat estimates, prompting a raised full-year outlook.
Johnson & Johnson reported first quarter 2026 revenue of $24.1 billion, up 9.9% year-over-year, with adjusted EPS of $2.70. Following the strong start to the...
Johnson & Johnson Q1 2026 Earnings Preview: What Analysts Expect on April 14, 2026
Consensus expectations for Q1 2026 put revenue at $23.44 billion and EPS at $2.68, while the stock's current price of $238.46 sits slightly below the average...
Johnson & Johnson to Reveal Varipulse Data Following European Launch
Johnson & Johnson will present 12-month interim results from its VARIPURE study at the 2026 PFA Summit. The company scheduled the data presentation for April...
Johnson & Johnson launches VARIPULSE in Europe, targeting common heart rhythm disorders
Johnson & Johnson launched the VARIPULSE Pro Platform in Europe following CE Mark approval. The device utilizes pulsed field ablation (PFA) to treat atrial...